Dr Besse on Results From the CARMEN-LC03 Trial in Nonsquamous NSCLC

Benjamin Besse, MD, PhD, director, clinical research, and medical oncologist at Institute Gustave Roussy, discusses findings from the phase 3 CARMEN-LC03 trial (NCT04154956), which is examining tusamitamab ravtansine in patients with advanced nonsquamous non–small cell lung cancer (NSCLC).